Tumor Board: Integrating Immunotherapy With Definitive and Perioperative Radiation Strategies in Stage I-III NSCLC

Activity Overview

The combination of increasing therapeutic options for patients with stage I-III non-small cell lung cancer (NSCLC) and screening efforts to detect early lung cancer creates a need for an informed multidisciplinary health care team for patients with stage I-III NSCLC. Given the established use of immunotherapy and targeted therapy in stage I-III NSCLC, timely molecular testing is essential to match the patient with the optimal treatment plan. Furthermore, efforts are ongoing to integrate new agents with local therapies, including radiation therapy.

This Tumor Board symposium brings together renowned experts in the management of early-stage and locally advanced NSCLC. The format replicates the dynamic, collaborative nature of multidisciplinary tumor boards, promoting the improvement of patient care.

This educational activity is an archive of the live virtual symposium held on September 26, 2026.

Target Audience

This educational activity is directed toward radiation oncologists, medical oncologists, thoracic oncologists, advanced practice providers, nurses, and other health care professionals involved in the management of stage I-III NSCLC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the rationale for combining immunotherapy and radiation therapy in managing early-stage and locally advanced NSCLC
• Evaluate contemporary clinical trial evidence supporting the integration of immunotherapy and targeted therapy with radiation-based treatment strategies across stages I-III NSCLC
• Integrate multidisciplinary assessment and molecular/biologic features into individualized treatment decisions
• Apply best practices for managing immune-related adverse events in combined modality therapy

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.

This activity may include discussion of investigational, unapproved, or off label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.